Key result
Active malignancy linked to ~78% higher 1-year major cardiovascular events risk vs prior cancer after AMI.
Why the study?
Patients with active or prior malignancy presenting with AMI have concurrent thrombotic and hemorrhagic risks, and evidence regarding antiplatelet choice, invasive management strategies, and outcomes across distinct oncological phenotypes remained fragmented.
Does percutaneous coronary intervention with drug-eluting stents and tailored P2Y12 receptor inhibition improve 1-year MACE and reduce BARC type 3 or 5 major bleeding in patients with acute myocardial infarction and active or prior malignancy?
Cohort (n=2,480)
Yes
Does percutaneous coronary intervention with drug-eluting stents and tailored P2Y12 receptor inhibition improve 1-year MACE and reduce BARC type 3 or 5 major bleeding in patients with acute myocardial infarction and active or prior malignancy?
In patients with acute myocardial infarction and malignancy, PCI with contemporary drug-eluting stents reduces 1-year MACE without increasing major bleeding, while clopidogrel with short-course DAPT offers superior safety over ticagrelor in high-bleeding-risk active cancer phenotypes such as GI/GU malignancies or severe thrombocytopenia.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for DES-PCI benefit in active malignancy; prospective trials needed to confirm and define optimal antiplatelet therapy.
Background: Patients with active or prior malignancy presenting with acute myocardial infarction (AMI) embody a complex clinical paradox characterized by concurrent hypercoagulability, baseline thrombocytopenia, vascular toxicity, and heightened hemorrhagic risk. Evidence regarding antiplatelet choice, invasive management strategies, and outcomes across distinct oncological phenotypes remains fragmented. Objectives: To evaluate contemporary 1-year clinical outcomes, establish an ischemic–hemorrhagic risk stratification scheme, and compare the effectiveness and safety of P2Y12 receptor inhibitors (clopidogrel vs. ticagrelor vs. prasugrel) across invasive/conservative management strategies, antithrombotic combinations, cancer stages, tumor types, and treatment-related cardiovascular phenotypes. Methods: A prospective, international, observational cohort study was conducted across 14 tertiary cardio-oncology centers from 2021 to 2025, enrolling 2,480 patients with AMI (STEMI: 38.4%; NSTEMI: 61.6%) and history of malignancy (active cancer: 58.2%; prior cancer: 41.8%). Cox proportional hazards modeling, propensity-score matching (PSM), and decision-tree risk stratification were performed. Primary endpoints included 1-year Major Adverse Cardiovascular Events (MACE: cardiovascular death, non-fatal reinfarction, or target-vessel revascularization) and Major Bleeding (BARC type 3 or 5). Results: At 1 year, patients with active malignancy experienced significantly higher MACE (22.4% vs. 12.8%; adjusted HR [aHR] 1.78, 95% CI 1.42–2.23; P < 0.001) and BARC 3/5 bleeding (14.2% vs. 6.1%; aHR 2.31, 95% CI 1.74–3.07; P < 0.001) compared to prior cancer. Percutaneous coronary intervention (PCI) with contemporary drug-eluting stents (DES) was associated with reduced 1-year MACE compared with conservative medical therapy (aHR 0.62, 95% CI 0.50–0.78), without increasing net major bleeding. In propensity-matched analyses, clopidogrel demonstrated superior safety with equivalent efficacy compared to ticagrelor in patients with baseline severe thrombocytopenia (platelets < 50 × 10^9/L) or gastrointestinal/genitourinary malignancies (BARC 3/5 bleeding: 8.1% vs. 17.6%; aHR 0.44, 95% CI 0.31–0.63; P < 0.001). Short-course dual antiplatelet therapy (DAPT; 1–3 months) followed by clopidogrel monotherapy yielded optimal net clinical benefit in high-bleeding-risk active cancer phenotypes. Conclusions: Management of AMI in cancer patients requires phenotypic precision. While invasive revascularization improves ischemic outcomes across most oncological cohorts, P2Y12 inhibition must be tailored: clopidogrel with short DAPT is preferable in active GI/GU malignancies or severe thrombocytopenia, whereas potent P2Y12 inhibitors offer ischemic benefit in prior cancer or low-bleeding-risk tumor phenotypes.
No takes yet. Share an insight, caveat, or question.
Bravo et al. (2026) conducted a cohort in Acute myocardial infarction in patients with active or prior malignancy (n=2,480). Active malignancy (and comparative P2Y12 inhibitor / PCI strategies) vs. Prior malignancy (or ticagrelor / conservative therapy) was evaluated on 1-year Major Adverse Cardiovascular Events (MACE: cardiovascular death, non-fatal reinfarction, or target-vessel revascularization) and Major Bleeding (BARC type 3 or 5) (aHR 1.78, 95% CI 1.42-2.23, p=<0.001). Active malignancy increased 1-year major cardiovascular events and BARC 3/5 bleeding vs prior cancer in AMI patients.
Synapse has enriched 10 related papers. Consider them for comparative context: